Piramal Pharma Ltd Share Price Today - Piramal Pharma Ltd Stock Price Live NSE/BSE

Piramal Pharma Ltd

NSE: PPLPHARMA BSE: 543635

₹161.23

(3.98)%

Tue, 03 Feb 2026, 00:09 pm

MTF 5xInvest in Piramal Pharma Ltd with 5x Leverage Buy with MTF

Market Cap206.37B

PE Ratio-

Dividend0.09

Health Technology

Pharmaceuticals: Major

24.5K

1 Day

0 (0%)

No Result Found

Summary

Market Cap
20636.58
Net Profit
91.13
P/B
3.66
Sector P/E
31.51
P/E
325.36
EV/EBITDA
20.63
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
16.31
ROCE (Industry)
15.98
RONW (Industry)
14.01
ROE
1.14
ROCE
6.43
Debt/Equity
0.60
EPS (TTM)
0
Dividend Yield
0.09
Book Value
60.77
Interest Cover
1.98

Analysis

No Result Found

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	34.86	34.86	34.86	34.95	34.95
FII	29.66	30.27	30.86	31.49	31.68
DII	15.69	14.89	14.26	14.78	14.10
Public	19.80	19.98	20.02	18.78	19.27
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

47.04

MACD

-5.26

50 DMA

170.95

200 DMA

193.55

Support and Resistance

Type	R1	R2	R3	PP	S1	S2	S3
Classic	236.14	199.41	177.04	162.68	140.31	125.95	89.22
Fibonacci	199.41	185.38	176.71	162.68	148.65	139.98	125.95
Camarilla	164.78	161.41	158.05	162.68	151.31	147.95	144.58

Pivots Level: Classic

+73.46

236.14

+36.73

199.41

+14.37

177.04

162.68

Pivot Point

LTP: 161.23

-22.36

140.31

-36.73

125.95

-73.46

89.22

Moving Average

SMAEMA

Period

Value

10-EMA
156.96
20-EMA
160.71
30-EMA
164.26
50-EMA
170.06
100-EMA
179.63
200-EMA
189.20

Announcement Date	Purpose	Action	Ex Date
28 Jan 2026	board-meetings	Quarterly Results
05 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
13 Jun 2025	agm
14 May 2025	dividend	₹0.14 Dividend /Share	16 Jul 2025
11 Jun 2024	agm
10 May 2024	dividend	₹0.11 Dividend /Share	12 Jul 2024
27 Jul 2023	rights	5:46 Rights Issue of Equity Shares	02 Aug 2023
25 May 2023	agm

Piramal Pharma Ltd

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Cipla Ltd

Torrent Pharmaceuticals Ltd

About Piramal Pharma Ltd

Piramal Pharma is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. We operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (“CDMO”) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (“APIs”), Finished dosage forms (“FDFs”), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (“CHG“) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and Piramal Consumer Healthcare (“PCH“) business, selling well-known OTC brands.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2020

Headquarters

CEO

Nandini Piramal

Employees

Contact

Website

http://www.piramalpharma.com

corporate.secretarial@piramal.com

Phone

91-22-3802-3000/4000

Location

Ground Floor Piramal Ananta, Agastya Corp.Park LBS MargKurl, Mumbai, Maharashtra, 400070

Year	History
2020	The company was incorporated on March 4, 2020 at Mumbai as a public limited company. The company acquired the pharmaceutical business from PEL. The company received a 20% Strategic Growth Investment by Carlyle. The company increased its stake to 100% in CCPL. Piramal Pharma and Navin Fluorine mutually agreed on Piramal increasing its stake to 100% in Convergence Chemicals. Piramal Pharma Solutions collaborated with Epirium Bio on an exclusive integrated development and manufacturing program for orphan drugs. Piramal Pharma Solutions announced an integrated development program with Bolt Biotherapeutics for immune-stimulating antibody conjugates and sterile fill-finish. Piramal Critical Care announced a strategic partnership with US-based pharmaceutical outsourcing facility Medivant Healthcare.
2021	The company acquired HPPL. Piramal Pharma Solutions announced the winner of its Inaugural Award for Excellence in Patient Centricity. Piramal Pharma Solutions entered into a Master Services Agreement with Plus Therapeutics, Inc. Piramal Pharma Limited's Consumer Products Division launched 'i-feel'.
2022	The company acquired a minority stake in Yapan Bio Private Limited. The Composite Scheme of Arrangement was sanctioned by the NCLT on August 12, 2022. Piramal Pharma Solutions announced the winner of its September 2022 Award for Excellence in Patient Centricity. Piramal Pharma Solutions launched ADCelerate, a rapid, integrated approach to taking ADCs to IND. Piramal Pharma Solutions held the grand opening ceremony for its new API plant at Aurora, Canada manufacturing site. Piramal Pharma Solutions' new API plant in Canada went online and initial production runs were successfully completed.
2023	The company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.

Client Name	Order Side	QTY	Avg Price	Date
GRAVITON RESEARCH CAPITAL LLP	Buy	6856958	219.7	20 Feb 2025
GRAVITON RESEARCH CAPITAL LLP	Sell	6856958	219.88	20 Feb 2025

piramal pharma limited News

Piramal Pharma Acquires Kenalog Brand for $100M

Piramal Pharma purchases Kenalog brand for up to $100 million to strengthen injectable portfolio and support global expansion strategy.

29 Jan 2026

co actions results

Piramal Pharma Reports Q3 Loss of ₹1.36B vs Profit

Piramal Pharma swings to consolidated net loss of ₹1.36 billion in Q3 from ₹37 million profit year-on-year, missing analyst estimates of ₹353 million profit significantly.

29 Jan 2026

co actions results

Piramal Pharma Board Meet Set for January 28, 2026

Piramal Pharma Limited has scheduled its board meeting for January 28, 2026, to consider Q3FY26 unaudited financial results. Trading window remains closed until January 30, 2026.

16 Jan 2026

co actions results

Piramal Pharma Gets FDA Form-483 for Lexington Unit

Piramal Pharma's Lexington facility receives US FDA Form-483 citing four issues following Good Manufacturing Practices inspection from December 3-10, 2025.

11 Dec 2025

stocks

Piramal Pharma Appoints CVC Capital Partner Amit Soni as Independent Director

Piramal Pharma's Board approved the appointment of Amit Soni, a Partner at CVC Capital, as Non-Executive Independent Director for a five-year term starting February 9, 2026, subject to shareholder approval. Soni brings over two decades of investment experience, having led CVC's India operations with $980 million deployed across 5 deals and previously worked with General Atlantic on major investments in technology, financial services and healthcare sectors.

08 Dec 2025

corporate governance

Showing 1–5 of 50

Rows per page:

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800